sodium tetradecyl sulfate has been researched along with HIV Coinfection in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De la Rosa-García, E; Esquivel-Pedraza, L; Lozada-Nur, F; Mohar, A; Ramírez-Amador, V; Súchil-Bernal, L; Volkow-Fernández, P | 1 |
1 review(s) available for sodium tetradecyl sulfate and HIV Coinfection
| Article | Year |
|---|---|
Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial.
Topics: Adult; Antineoplastic Agents, Phytogenic; Double-Blind Method; Follow-Up Studies; HIV Infections; Humans; Injections, Intralesional; Male; Middle Aged; Mouth Neoplasms; Sarcoma, Kaposi; Sclerosing Solutions; Sodium Tetradecyl Sulfate; Treatment Outcome; Vinblastine | 2002 |
1 trial(s) available for sodium tetradecyl sulfate and HIV Coinfection
| Article | Year |
|---|---|
Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial.
Topics: Adult; Antineoplastic Agents, Phytogenic; Double-Blind Method; Follow-Up Studies; HIV Infections; Humans; Injections, Intralesional; Male; Middle Aged; Mouth Neoplasms; Sarcoma, Kaposi; Sclerosing Solutions; Sodium Tetradecyl Sulfate; Treatment Outcome; Vinblastine | 2002 |